IDH1 Inhibitor Treatment for Relapsed or Refractory Blood Cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called olutasidenib in Japanese patients with acute myeloid leukemia (a serious blood cancer) that has come back or stopped responding to previous treatment. The drug targets a specific genetic change (IDH1 mutation) that some leukemia cells have, and may help patients whose cancer is difficult to treat.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a Japanese citizen able to give written informed consent
- You have been diagnosed with acute myeloid leukemia (AML), a type of blood cancer (but not acute promyelocytic leukemia with a specific genetic change)
- Your AML has relapsed (come back) or is refractory (stopped responding to earlier treatment)
- Your cancer cells have a confirmed IDH1 gene mutation
- You do not have an IDH2 gene mutation and have not been treated with IDH2 inhibitor drugs before
- You have tolerated IDH1 inhibitor drugs in the past or have no known allergy to them
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called olutasidenib, either alone or with other treatments, to see if it can help keep your AML in remission after you've finished your first round of therapy. It's for people whose AML has a specific change in the IDH1 gene.
This trial tests an oral drug called olutasidenib in people with certain low-risk blood cancers or a pre-cancer condition. It may help by targeting a specific genetic change (IDH1 mutation) found in your blood cells.
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
This trial tests the drug olutasidenib for people with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. It is for patients who have already received the drug venetoclax and have an IDH1 mutation in their leukemia cells.
This trial combines three drugs—decitabine, venetoclax, and a targeted therapy (olutasidenib)—to treat acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It may also be an option for people newly diagnosed with AML who cannot receive intense chemotherapy.
This trial tests a combination of olutasidenib with other targeted drugs for people with certain blood cancers that have returned or not responded to treatment. It focuses on patients who have both an IDH1 mutation and a second activating mutation in specific signaling genes.
Hear when a new Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.